Special Feature Webinar: Hormone Therapy Unlocked: Case Studies in Diagnosing and Managing Hypoactive Sexual Desire Disorder and Menopausal Hormone Therapy

August 13, 2025

This interactive Special Feature Webinar uses real-world case studies to guide clinicians through the complexities of diagnosing and managing hypoactive sexual desire disorder and menopausal symptoms in women. It is a follow-on activity to the February 2025 CCSS session titled Hormone Therapy Unlocked: Overcoming Barriers to Better Care.

CE/CME available: As the presentation date (August 13) approaches, we will update this page to identify the types of CE/CME credit that will be available for this event. The amount of CE/CME awarded will be 1.5 hours/CE/CME.

Target Audience

TBA

Learning Objectives

Identify diagnostic criteria for HSDD and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener (DSDS) to guide clinical decision-making.
Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, SHBG), and assessing informed consent for off-label use.
Explain the evidence, risks, and benefits of testosterone therapy in women, and design a follow-up plan: including FDA-approved options and monitoring protocols for labs, efficacy and side effects.
Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making.
Assess suitability for MHT in women with chronic disease, using a thorough history and risk stratification based on current guidelines.
Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of timing hypothesis and type of hormone used (e.g., transdermal vs oral).
Formulate an individualized MHT plan and follow-up protocol: selecting appropriate estrogen route/dose and progestogen (if uterus is intact), while considering symptom burden and risk profile. Review optimization and adjustments during therapy.
Recognize the clinical significance of untreated vasomotor symptoms (VMS), including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline.

Course summary

Course opens:

06/23/2025

Course expires:

08/27/2025

Event starts:

08/13/2025 - 1:00pm EDT

Event ends:

08/13/2025 - 2:30pm EDT

Add to calendar:

View the presentation in Microsoft Teams at:

https://dod.teams.microsoft.us/l/meetup-join/19%3adod%3ameeting_cac3243d862f4a48a3f47917a99e2ac8%40thread.v2/0?context=%7b%22Tid%22%3a%228903a443-af33-4ed4-acf5-ee613bcb2f59%22%2c%22Oid%22%3a%229417ac16-7564-40a8-901b-4f24688f9a62%22%7d

Featured Faculty:

TBA

Presenting Faculty:

Rebbecca Hertel, DO, MSCP
Family Physician, Certified Menopause Practitioner, and Founder of Osteopathic Midlife Health

Heather Quaile, DNP, WHNP-BC, AFN-C, CSC, I.F., FAANP
Scientific Committee Chair for the International Society for the Study of Women’s Sexual Health and Founder of the Sexual Health Optimization and Wellness Center

Air Force Lt. Col. Samantha Simpson, M.D.
Chief of the Reproductive Endocrinology and Infertility Division and Program Director for the SAUSHEC OB/GYN Residency Program, Brooke Army Medical Center

Retired Air Force Col. Christine Kress, DNP, APRN, WHNP-BC, NEA-BC, MSCP
Women’s Health Nurse Practitioner and Certified Menopause Practitioner, Heather Hirsch MD Collaborative

Aoife O’Sullivan, M.D., NCMP
Family Physician, Certified Menopause Practitioner, and Founder of Portland Menopause Doc

Disclosure: DHA J-7 staff, planning committee members, and content reviewers have no financial or non-financial interest to disclose. All faculty members have no financial or non-financial interest to disclose.

Speaker(s)